Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 13:13:1032199.
doi: 10.3389/fendo.2022.1032199. eCollection 2022.

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data

Shichao Dong  1 , Chuan Sun  2
Affiliations

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data

Shichao Dong et al. Front Endocrinol (Lausanne). .

Abstract

Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI caused by different GLP-1RA. In this study, Adverse Event Reporting System (FAERS) data were used to compare the association between different GLP-1RA and AKI in the real world.

Methods: FAERS data from January 2004 to December 2021 were mined using disproportionality analysis and Bayesian analysis to determine the correlation between different GLP-1RA and AKI, and the onset time, mortality, and hospitalization rate of different GLP-1RA were analyzed.

Results: We identified 2670 cases of AKI events associated with GLP-1RA, of which liraglutide was the most commonly reported (34.98%). The patients with AKI were mainly males (47.94%), and the age group was mainly 45-84 years old (73.15%). obese patients with weight more than 99kg (24.42%) were more likely to have AKI. According to different signal mining methods, reporting odds ratio (ROR) (1.50, 95% confidence interval =1.41-1.60) and Bayesian confidence Propagation neural network (0.57, 95% confidence interval =0.54), liraglutide was more strongly associated with AKI than other GLP-1RA. The median time to onset of AKI was 63 days [quartile range (IQR): 15-458.5 days]. In addition, the hospitalization rate and fatality rate of patients with GLP-1RA-related AKI were 45.28% and 4.23% respectively.

Conclusions: Based on the data in the FAERS database, we analyzed the risk, onset time, and adverse reaction outcomes of GLP-1RA-induced AKI in detail. The results showed that liraglutide had the highest risk of AKI. From the early stage of treatment, we need to monitor patients' renal function regularly, especially for patients with high kidney risks such as obesity and age.

Keywords: acute kidney injury; adverse event reporting system; data mining; glucagon-like peptide-1 receptor agonist; onset time; outcome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Process of screening cases of acute kidney injury caused by GLP-1 receptor agonists from FAERS database. FAERS, FDA Adverse Event Reporting System; GLP,glucagon-like peptide-1.
Figure 2
Figure 2
Distribution curve of the onset time of acute kidney injury caused by GLP-1RA.
Figure 3
Figure 3
Mortality and hospitalization rate of acute kidney injury caused by GLP-1RA.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Deacon CF, Ahrén B. Physiology of incretins in health and disease. Rev Diabetes Stud (2011) 8(3):293–306. doi: 10.1900/RDS.2011.8.293 - DOI - PMC - PubMed
    1. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 60(4):470–512. doi: 10.1124/pr.108.000604 - DOI - PMC - PubMed
    1. Górriz JL, Soler MJ, Navarro-González JF, García-Carro C, Puchades MJ, D'Marco L, et al. . GLP-1 receptor agonists and diabetic kidney disease: A call of attention to nephrologists. J Clin Med (2020) 9(4):947. doi: 10.3390/jcm9040947 - DOI - PMC - PubMed
    1. Mori Y, Matsui T, Hirano T, Yamagishi SI. GIP as a potential therapeutic target for atherosclerotic cardiovascular disease-a systematic review. Int J Mol Sci (2020) 21(4):1509. doi: 10.3390/ijms21041509 - DOI - PMC - PubMed
    1. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med (2016) 375:311–22. doi: 10.1056/NEJMoa1603827 - DOI - PMC - PubMed

Substances

LinkOut - more resources